Accéder au contenu
Merck

R9281

Rotigotine hydrochloride

≥98% (HPLC)

Synonyme(s) :

(−)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol hydrochloride, (−)-N 0437, N 0923, Neupro, SPM 962

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule empirique (notation de Hill) :
C19H25NOS·HCl
Numéro CAS:
125572-93-2
Poids moléculaire :
351.93
NACRES:
NA.77
PubChem Substance ID:
329824046
UNSPSC Code:
12352200
MDL number:
MFCD00906149

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

InChI

1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1

SMILES string

Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2

InChI key

CEXBONHIOKGWNU-NTISSMGPSA-N

assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to off-white

solubility

DMSO: >10 mg/mL

originator

UCB Inc.

storage temp.

room temp

Quality Level

100

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Biochem/physiol Actions

Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Classe de stockage

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000140733
0000085433
0000026628
0000026629
0000025067

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Lawrence W Elmer et al.
Parkinsonism & related disorders, 18(5), 488-493 (2012-02-14)
This prospective, open-label extension (SP702; NCT00594165) of a 6-month double-blind, randomized study investigated the long-term safety and tolerability of rotigotine transdermal system in early Parkinson's disease (PD). Patients with early-stage idiopathic PD received transdermal rotigotine for up to 6 years
Santiago Perez-Lloret et al.
Fundamental & clinical pharmacology, 27(1), 81-95 (2012-02-11)
Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe
Nikos Gorgoraptis et al.
Brain : a journal of neurology, 135(Pt 8), 2478-2491 (2012-07-05)
Hemispatial neglect following right-hemisphere stroke is a common and disabling disorder, for which there is currently no effective pharmacological treatment. Dopamine agonists have been shown to play a role in selective attention and working memory, two core cognitive components of
S R Schreglmann et al.
Parkinsonism & related disorders, 18(2), 207-209 (2011-10-28)
Dopaminergic drugs are the mainstay of treatment for restless legs syndrome (RLS). We analyzed the frequency and clinical characteristics of impulse control disorders (ICD) in patients with RLS on transdermal rotigotine treatment. Retrospective case series at a university movement disorder
Yuichi Inoue et al.
Progress in neuro-psychopharmacology & biological psychiatry, 40, 326-333 (2012-10-30)
The present study aimed to examine the long-term efficacy and safety of rotigotine treatment for restless legs syndrome (RLS), as well as the rate of clinically significant augmentation, in a 1-year open-label study of Japanese subjects. Japanese patients with RLS
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique